Medical Device Control Office (MDCO) โ Hong Kong's Medical Device Regulator
The Medical Device Control Office (MDCO), under the Department of Health of the Hong Kong Special Administrative Region, regulates medical devices under the Medical Devices Ordinance (Cap. 696). Enacted in 2023 and being progressively implemented, the Ordinance introduces a mandatory registration system for medical devices classified under the Global Harmonization Task Force (GHTF) framework.
Under the Cap. 696 framework, all medical devices must be registered with MDCO before supply in Hong Kong. Manufacturers must hold an Establishment Licence, and each device must be product-registered. The Ordinance introduced a phased implementation timeline, with higher-risk (Class C and D) devices required to register first, followed by Class B and A devices. Foreign manufacturers may appoint a Hong Kong-based authorized representative to manage registrations.
Hong Kong's strategic value extends beyond its 7.5M population. As a global financial center with internationally recognized regulatory standards and a sophisticated hospital sector (including major private hospitals), Hong Kong registration carries weight as a credentialing signal for Greater China market strategy โ particularly for manufacturers planning subsequent Mainland China NMPA registration.
- Cap. 696 Ordinance โ phased mandatory registration from 2023 onward (Class C/D first)
- Establishment Licence and Product Registration both required before supply
- GHTF classification framework โ aligned with international risk classification standards
- HK MDCO registration recognized as evidence of quality in Mainland China NMPA dossiers
- Post-market surveillance, adverse event reporting, and licence renewal required
MDCO Product Registration Timelines by Device Class
Target processing times under the Cap. 696 implementation โ Establishment Licence runs in parallel.
Integrated Services for Hong Kong MDCO Registration
MDCO Product Registration
End-to-end Cap. 696 product registration โ Establishment Licence application, technical dossier preparation (GHTF format), MDCO portal submission, query response, and registration maintenance. Class AโD and IVD registration included.
Establishment Licence
Application and management of the MDCO Establishment Licence โ required for all manufacturers, importers, and distributors of medical devices in Hong Kong. Covers all Cap. 696 compliance obligations and annual renewal management.
Greater China Strategy
Hong Kong MDCO registration positioned as part of a Greater China market entry strategy โ including strategic advice on sequencing HK approval with Mainland China NMPA registration, leveraging HK clinical evidence and CE/FDA approvals for NMPA dossier strengthening.
Why JNPMEDI APAC for Hong Kong MDCO Registration
Hong Kong's Medical Devices Ordinance Cap. 696 introduces a mandatory registration framework that is being implemented in phases from 2023 onward. Many manufacturers are navigating this transition for the first time. JNPMEDI APAC's team tracks MDCO implementation updates, phased deadlines, and transition guidance โ ensuring compliance without disruption to existing supply arrangements.
For manufacturers targeting Mainland China, Hong Kong MDCO registration provides strategic advantages. CE and FDA approvals, combined with HK MDCO registration, create a credentialing package that supports Mainland China NMPA (National Medical Products Administration) applications โ particularly for Class III devices seeking expedited pathways under NMPA's innovative device programs.
Hong Kong's private hospital sector โ including major international hospitals โ operates at world-class standards and commands premium pricing for innovative devices. Hospital Authority procurement and private sector adoption both require MDCO registration. For medical technology companies entering Asia, Hong Kong provides a premium reference market with shorter approval timelines than most APAC jurisdictions.
Hong Kong MDCO Registration โ FAQ
The Medical Devices Ordinance Cap. 696 is Hong Kong's dedicated medical device regulatory framework, enacted in 2023 and being implemented in phases. It introduces mandatory product registration for all medical devices and an Establishment Licence requirement for manufacturers, importers, and distributors. Implementation is phased by device class โ Class C and D devices were required to register first, followed by Class B and A devices over subsequent years. All new devices must be registered before supply.
An Establishment Licence is required under Cap. 696 for all entities that manufacture, import, or distribute medical devices in Hong Kong. The licence holder takes on regulatory responsibility for device safety and post-market compliance. Foreign manufacturers without a Hong Kong presence typically appoint a local authorized representative who holds the Establishment Licence. JNPMEDI APAC coordinates Establishment Licence acquisition and management through our Hong Kong partner network.
MDCO registration demonstrates regulatory compliance to international standards (GHTF-aligned) and, combined with CE/FDA/PMDA approvals, creates a credentialing package that can support Mainland China NMPA applications. Specifically, under NMPA's innovative device fast-track pathways and clinical data recognition policies, prior approvals from internationally recognized regulators (including MDCO) are considered supportive evidence. JNPMEDI APAC advises on HKโNMPA sequencing strategy as part of Greater China market entry planning.
Yes. MDCO accepts CE marking under EU MDR/IVDR and FDA clearance/approval as supporting documentation for product registration. While MDCO conducts its own review under Cap. 696, reference approvals from recognized regulatory bodies can streamline the technical assessment and reduce documentation requirements. JNPMEDI APAC prepares CE/FDA-referenced dossiers optimized for the MDCO submission process.